Loading company
Palatin Technologies, Inc.
PTN · Nasdaq · ·
$9.38-5.0%Sep 29 close
- 1M
- -10.5%
- 6M
- -49.4%
PTN · Nasdaq · ·
$9.38-5.0%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $300.8K | $0.00 | — |
| Profit | -$4.4M | -$2.2M | -95.47% |
| Profit per share | -$1.33 | $1.74 | -176.44% |
| Free Cash Flow | -$2.7M | -$6.5M | +58.47% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Palatin Technologies, Inc. has no earnings call transcript available.
“With the establishment of pharmacotherapy as the primary treatment for the millions of obese patients and the high discontinuation rate (67%) of obese patients on current therapies resulting from side effects and a weight-loss plateau effect in the first year, we believe our MC4R long-acting peptide and oral small molecule compounds could address the unmet needs and challenges of these treatments,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Receptor Agonists The melanocortin receptor (“MCR”) system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects. Many tissues and immune cells located in the eye (and other places, for example the gut and kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Palatin Technologies, Inc.’s Item 2.02 8-K filed November 14, 2024; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.